{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:23Z","timestamp":1791232463199,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":294,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:p>Mifepristone (RU486) is a potent antiprogestagen, and at high doses it also acts as an antiglucocorticoid drug. Mifepristone, administered as a single 600\u2003mg dose, is commonly employed to induce medical abortion in conjunction with prostaglandins. The long\u2010term safety profile of mifepristone, especially at high doses, is less well\u2010established. Long\u2010term mifepristone is considered efficacious in treating uterine myomas, endometriosis (25\u2013100\u2003mg\/day), and possibly in inoperable meningiomas (200\u2003mg\/day), as well as inoperable Cushing's syndrome. Many animal studies document an antiproliferative effect (antioestrogenic), as do some reports in humans. However, there are also data to suggest that, as an antiprogestagen, mifepristone may promote an unopposed oestrogen milieu, and thus have a proliferative effect upon the endometrium.<\/jats:p><jats:p>We hereby describe the first reported case of an adolescent female with Cushingoid features and morbid osteoporosis who was treated with mifepristone for its antiglucocorticoid effect (400\u2003mg\/day) in an attempt to prevent further bone loss. The patient's striae, weight gain, and buffalo hump markedly improved, and further bone loss was halted. However, with each of the two 6\u2010month courses of mifepristone (9\u2003months apart) she developed massive simple endometrial hyperplasia and a markedly enlarged uterus. This reversed to normal after cessation of mifepristone treatment.<\/jats:p><jats:p>In conclusion, High doses of the antiprogestagen mifepristone over\u00a0a prolonged period of time may promote an unopposed oestrogen milieu leading to\u00a0endometrial hyperplasia. Therefore, interval pelvic\u00a0imaging in women who receive long\u2010term mifepristone may be prudent.<\/jats:p>","DOI":"10.1046\/j.1365-2265.2001.01026.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:48:35Z","timestamp":1047379715000},"page":"399-404","source":"Crossref","is-referenced-by-count":63,"title":["Long\u2010term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia"],"prefix":"10.1111","volume":"54","author":[{"given":"Ron S.","family":"Newfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving M.","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Isacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"New","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2781282"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-59-1-25"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a019151"},{"key":"e_1_2_5_5_1","first-page":"S18","article-title":"Glucocorticoids and glucocorticoid antagonists: Lessons from RU 486","volume":"34","author":"Chrousos G.P.","year":"1988","journal-title":"Kidney International"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.4.793"},{"key":"e_1_2_5_7_1","unstructured":"Crum C.P.(1994) Pathologic Basis of Disease. 5th edn. pp. 1033\u20131088 W.B. Saunders Company Philadelphia."},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/9.suppl_1.77"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)58022-4"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/9.suppl_1.116"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-73-1-187"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.6.486"},{"key":"e_1_2_5_14_1","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1016\/S0021-9258(17)32664-9","article-title":"RU486 exerts antiestrogenic activities through a novel progesterone receptor A form\u2010mediated mechanism","volume":"269","author":"McDonnell D.P.","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001703-199406000-00012"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0015-0282(16)57478-0","article-title":"Endometrial effects of long\u2010term low\u2010dose administration of RU486","volume":"63","author":"Murphy A.A.","year":"1995","journal-title":"Fertility and Sterility"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.1.14"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-3-536"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0940-9602(11)80170-6"},{"key":"e_1_2_5_20_1","first-page":"763","article-title":"Aromatase activities of endometrial carcinomas and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease","volume":"45","author":"Sasaki H.","year":"1993","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(96)00178-1"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.2.440"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.2.269"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308053290607"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.36.040196.000403"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01026.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01026.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.2001.01026.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:07:49Z","timestamp":1697504869000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.2001.01026.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1046\/j.1365-2265.2001.01026.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01026.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}